OncRef

Clinical Trial: NCT02638090

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:H. Lee Moffitt Cancer Center and Research Institute
Information Provided By:H. Lee Moffitt Cancer Center and Research Institute
Last Update Posted:2026-10-06

Study Overview

Brief Summary

The main purpose of this study is to see whether the combination of two drugs called pembrolizumab and vorinostat can help people with advanced lung cancer. Researchers also want to find out if the combination of pembrolizumab and vorinostat is safe and tolerable. This study will compare the effects of the combination of two drugs called pembrolizumab and vorinostat with the effects of pembrolizumab alone. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for use to treat a deadly skin cancer called melanoma and lung cancer and vorinostat to treat some forms of blood and lymph node cancers.

Official Title

A Phase I/II Study of Pembrolizumab and Vorinostat in Patients With Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC

Conditions

Lung Cancer, Non-small Cell Lung Cancer

Intervention / Treatment

  • Drug: Vorinostat
  • Drug: Pembrolizumab

Other Study ID Numbers

  • MCC-18494

Start Date (Actual)

2016-03-22

Primary Completion Date (Actual)

2024-01-21

Study Completion Date (Estimated)

2027-06

Enrollment (Actual)

120

Study Type

Interventional

Phase

Phase 1, Phase 2